QNCX Quince Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 14, 2026
$29,20
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$15,1052 haftanın en düşüğü
$910,0052 haftanın en yükseği
Piyasa Değeri (MRQ)
$30M
P/E
-0.2
Hisse Başına Kâr
$-1.68
rozetleriniz
52 Haftlık Aralık
$15–$910
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$75
P/E
-0.2
ROE
700.5%
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
QNCX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$29.20
Piyasa Değeri (MRQ)
$30M
P/E
-0.2
Hisse Başına Kâr
$-1.68
ROE
700.5%
D/E Borç/Özsermaye (MRQ)
-0.0
52 Haftlık Aralık
$15–$910
QNCX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 30 Haziran 2026 | 1-for-20 | Ters |
| 13 Nisan 2026 | 1-for-10 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Hisse Başına Kâr$-1.682021-12-31 → 2025-12-31
Serbest Nakit Akışı$-42M2019-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | QNCX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -0.25Y ort. ≈-1.9 | ≈-1.9 | · | · | |
| F/D (MRQ) | -0.85Y ort. ≈0.3 | ≈0.3 | · | · | |
| EV / EBITDA | -0.6 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -0.65Y ort. ≈-3.2 | ≈-3.2 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -0.65Y ort. ≈-3.2 | ≈-3.2 | · | · | |
| EV / FCF (TTM) | 1.8 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | -0.85Y ort. ≈5.1 | ≈5.1 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | QNCX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA | -80.8%5Y ort. ≈-48.7% | ≈-48.7% | -103.8% | En üst düzey | |
| ROE | 700.5%5Y ort. ≈78.0% | ≈78.0% | -323.9% | En üst düzey | |
| ROIC | 341.4%5Y ort. ≈14.7% | ≈14.7% | · | · |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | QNCX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | -0.0 | · | · | · | |
| Cari Oran (MRQ) | 14.55Y ort. ≈10.6 | ≈10.6 | 1.6 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 0.15Y ort. ≈10.1 | ≈10.1 | 1.4 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-18.9%
Sonraki Rapor
Kas 10, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 14, 2026 | $-12.31 | $-18.24 | 32.5% |
| 31 Mart 2026 | May 11, 2026 | $57.60 | $-52.22 | 210.3% |
| 31 Aralık 2025 | $-142.00 | $-38.52 | -268.7% | |
| 30 Eylül 2025 | $-50.00 | $-44.15 | -13.3% | |
| 30 Haziran 2025 | $-46.00 | $-51.34 | 10.4% | |
| 31 Mart 2025 | $-3.40 | $-2.32 | -46.5% | |
| 31 Aralık 2024 | $-0.28 | $-0.18 | -56.9% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $35M | $19M | $9M | $25M | $61M | $61M | $30M | $10M | |
| SG&A Expense | $15M | $18M | $18M | $26M | $30M | $18M | $9M | $2M | |
| Operating Expenses | $58M | $57M | $35M | $52M | $90M | $79M | $39M | $12M | |
| Operating Income | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | $-12M | |
| Interest Expense | · | · | · | · | · | · | · | $957.0K | |
| Interest Income | $1M | $3M | $3M | $1M | $620.0K | $2M | $2M | $806.0K | |
| Other Non-op | $486.0K | $-676.0K | $-102.0K | $-997.0K | $-247.0K | $0 | $0 | · | |
| Pretax Income | $-81M | $-57M | $-32M | $-52M | $-90M | $-77M | $-37M | · | |
| Income Tax | $3M | $87.0K | $-197.0K | $-284.0K | $0 | $0 | $0 | $0 | |
| Net Income | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | $-12M | |
| EPS (Basic) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| EPS (Diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · | |
| Shares (Basic) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| Shares (Diluted) | 50,096,897 | 43,262,269 | 37,237,149 | 33,496,534 | 29,718,506 | · | · | · | |
| EBITDA | $-58M | $-57M | $-35M | $-52M | $-90M | $-79M | $-39M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6M | $6M | $75M | $41M | $29M | $134M | $51M | $25M | |
| Short-term Investments | $12M | · | · | · | · | · | · | · | |
| Receivables | · | · | · | $0 | · | · | · | · | |
| Prepaid Expense | $5M | $3M | $2M | $4M | $5M | $4M | $6M | $868.0K | |
| Other Current Assets | $54.0K | $84.0K | $81.0K | $276.0K | $367.0K | $694.0K | $688.0K | $68.0K | |
| Current Assets | $23M | $44M | $77M | $94M | $112M | $138M | $106M | $73M | |
| PP&E (Net) | $595.0K | $315.0K | $234.0K | $393.0K | $263.0K | $427.0K | $709.0K | $283.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | $378.0K | |
| Accum. Depreciation | $844.0K | $639.0K | $507.0K | $185.0K | $959.0K | $615.0K | $283.0K | $95.0K | |
| Goodwill | · | $0 | $18M | $0 | $0 | · | · | · | |
| Intangibles | $68M | $60M | $64M | $6M | $0 | · | · | · | |
| Other Non-current Assets | $2M | $10M | $9M | $0 | $194.0K | $39.0K | $217.0K | $10.0K | |
| Total Assets | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Accounts Payable | $2M | $3M | $2M | $570.0K | $5M | $4M | $3M | $495.0K | |
| Accrued Liabilities | $11M | $4M | $3M | $2M | $9M | $13M | $6M | $962.0K | |
| Current Liabilities | $43M | $7M | $10M | $3M | $14M | $17M | $9M | $1M | |
| Capital Leases | $330.0K | $394.0K | $321.0K | $0 | $420.0K | $208.0K | · | · | |
| Deferred Tax | $0 | $5M | $5M | $248.0K | $0 | · | · | · | |
| Other Non-current Liabilities | $2M | $685.0K | $587.0K | $0 | · | · | · | · | |
| Total Liabilities | $129M | $84M | $83M | $3M | $15M | $17M | $9M | $1M | |
| Long-term Debt | $0 | $14M | $13M | $0 | · | · | · | · | |
| Total Debt | $18M | · | · | · | · | · | · | · | |
| Common Stock | $0 | $44.0K | $43.0K | $36.0K | $30.0K | $29.0K | $27.0K | $3.0K | |
| Paid-in Capital | $419M | $407M | · | · | · | · | · | · | |
| Retained Earnings | $-460M | $-376M | $-320M | $-288M | $-237M | $-147M | $-70M | $-33M | |
| AOCI | $6M | $-35.0K | $3M | $-289.0K | $-79.0K | $313.0K | $60.0K | $-49.0K | |
| Stockholders' Equity | $-36M | $30M | $85M | $101M | $119M | $172M | $115M | $-33M | |
| Liabilities + Equity | $94M | $114M | $168M | $104M | $133M | $189M | $124M | $73M | |
| Shares Outstanding | 278,627 | 220,009 | 42,973,215 | 36,136,480 | 30,074,412 | 29,543,222 | 26,869,413 | 3,412,366 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K | $332.0K | $188.0K | $51.0K | |
| Stock-based Comp | $5M | $5M | $5M | $17M | $30M | $14M | $2M | $155.0K | |
| Deferred Tax | $-6M | $-45.0K | $-258.0K | $284.0K | · | · | · | · | |
| Operating Cash Flow | $-41M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | $-12M | |
| CapEx | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K | |
| Investing Cash Flow | $23M | $22M | $-6M | $18M | $59M | $-52M | $-18M | $-47M | |
| Stock Issued | · | · | $0 | $608.0K | $0 | · | · | · | |
| Net Stock Activity | · | · | $0 | $608.0K | · | · | · | · | |
| Financing Cash Flow | $18M | $-5M | $143.0K | $707.0K | $7M | $119M | $77M | $76M | |
| Net Change in Cash | $-403.0K | $-15M | $-24M | $-25M | $3M | $16M | $26M | · | |
| Free Cash Flow | $-42M | $-32M | $-18M | $-44M | $-63M | $-51M | $-33M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROA | -80.8% | -40.2% | -23.1% | -43.6% | -55.8% | -49.0% | -37.5% | · | |
| ROE | 700.5% | -151.4% | -37.3% | -50.4% | -71.6% | -42.7% | -30.5% | · | |
| ROIC | 341.4% | -190.3% | -40.9% | -51.4% | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 | 8.1 | 11.9 | · | |
| Quick Ratio | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 | 7.9 | 5.8 | · | |
| Debt / Equity | -0.5 | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.64 | $0.69 | $1.98 | $2.78 | $3.94 | $5.83 | $4.30 | · | |
| Cash Flow / Share | $-0.83 | $-0.74 | $-0.49 | $-1.31 | · | · | · | · | |
| Cash / Share | $0.10 | $0.93 | $1.75 | $2.50 | $3.55 | $4.53 | $1.91 | · | |
| EPS (TTM) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-84M | $-57M | $-31M | $-52M | $-90M | $-77M | $-37M | · | |
| Market Cap | $187M | $82M | $45M | $23M | $380M | $821M | $1.51B | · | |
| Enterprise Value | $199M | · | · | · | · | · | · | · | |
| P/E | -2.0 | -1.4 | -1.2 | -0.4 | -4.2 | · | · | · | |
| P/B | -5.2 | 2.7 | 0.5 | 0.2 | 3.2 | 4.8 | 13.1 | · | |
| P / Tangible Book | · | · | 11.9 | 0.2 | 3.2 | 4.8 | · | · | |
| P / Cash Flow | -4.5 | -2.6 | -2.5 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| P / FCF | -4.5 | -2.6 | -2.4 | -0.5 | -6.0 | -16.1 | -45.3 | · | |
| EV / EBITDA | -3.4 | · | · | · | · | · | · | · | |
| EV / FCF | -4.8 | · | · | · | · | · | · | · | |
| Earnings Yield | -50.1% | -70.0% | -80.0% | -241.8% | -24.0% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $7M | $13M | $8M | $7M | $8M | $6M | $5M | $4M | $4M | $3M | $1M | $1M | $3M | $3M | $2M | |
| SG&A Expense | $17M | $4M | $4M | $3M | $3M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $80M | $15M | $19M | $13M | $10M | $15M | $12M | $6M | $28M | $11M | $10M | $6M | $6M | $13M | $6M | $8M | |
| Operating Income | $-80M | $-15M | $-19M | $-13M | $-10M | $-15M | $-12M | $-6M | $-28M | $-11M | $-10M | $-6M | $-6M | $-13M | $-6M | $-8M | |
| Interest Income | $584.0K | $160.0K | $227.0K | $300.0K | $311.0K | $406.0K | $536.0K | $683.0K | $823.0K | $887.0K | $1M | $959.0K | $805.0K | $700.0K | $536.0K | $315.0K | |
| Other Non-op | $152.0K | $2M | $660.0K | $-58.0K | $-29.0K | $-87.0K | $-518.0K | $150.0K | $91.0K | $-399.0K | $467.0K | $-216.0K | $-107.0K | $-246.0K | $204.0K | $-616.0K | |
| Pretax Income | · | · | · | · | · | $-15M | · | · | · | $-11M | · | · | · | · | · | · | |
| Income Tax | $75.0K | $-5M | $3M | $-46.0K | $67.0K | $47.0K | $7.0K | $13.0K | $36.0K | $31.0K | $51.0K | $0 | $0 | $-248.0K | $0 | $0 | |
| Net Income | $-75M | $36M | $-39M | $-13M | $-16M | $-15M | $-12M | $-5M | $-28M | $-11M | $-9M | $-5M | $-5M | $-12M | $-6M | $-8M | |
| EPS (Basic) | $-12.31 | $3.60 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| EPS (Diluted) | $-12.31 | $2.88 | $-0.75 | $-0.25 | $-68.75 | $-3.42 | $-0.28 | $-0.13 | $-0.64 | $-0.26 | $-0.21 | $-0.15 | $-0.14 | $-0.34 | $-0.09 | $-0.22 | |
| Shares (Basic) | 6,132,845 | 9,120,267 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| Shares (Diluted) | 6,132,845 | 9,190,354 | · | 53,951,371 | 233,431 | 4,394,119 | · | 43,164,136 | 43,096,374 | 43,010,212 | · | 36,073,040 | 35,917,592 | 35,855,200 | · | 35,612,749 | |
| EBITDA | $-80M | $-15M | · | $-13M | $-10M | $-15M | · | $-6M | $-28M | $-11M | · | $-6M | $-6M | $-13M | · | $-8M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $116M | $18M | $6M | $6M | $17M | $8M | $6M | $48M | $59M | $68M | · | $21M | $21M | $42M | · | $22M | |
| Short-term Investments | $0 | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $500.0K | · | · | · | · | |
| Prepaid Expense | $7M | $7M | $5M | $3M | $3M | $2M | $3M | $4M | $4M | $3M | $2M | $1M | $983.0K | $2M | $4M | $4M | |
| Other Current Assets | $393.0K | $24.0K | $54.0K | $96.0K | $55.0K | $32.0K | $84.0K | $55.0K | $79.0K | $48.0K | $81.0K | $92.0K | $143.0K | $179.0K | $276.0K | $336.0K | |
| Current Assets | $123M | $26M | $23M | $29M | $37M | $34M | $44M | $52M | $63M | $70M | $77M | $85M | $89M | $92M | $94M | $98M | |
| PP&E (Net) | $506.0K | $550.0K | $595.0K | $616.0K | $573.0K | $448.0K | $315.0K | $208.0K | $246.0K | $234.0K | $234.0K | $5.0K | $6.0K | $6.0K | $393.0K | $375.0K | |
| Accum. Depreciation | $882.0K | $856.0K | $844.0K | $807.0K | $777.0K | $691.0K | $639.0K | $667.0K | $566.0K | $530.0K | $507.0K | $13.0K | $12.0K | $12.0K | $185.0K | $159.0K | |
| Goodwill | · | · | · | $0 | · | · | $0 | $0 | $0 | $17M | $18M | $0 | $0 | $0 | $0 | $0 | |
| Intangibles | $0 | $0 | $68M | $68M | $68M | $62M | $60M | $65M | $62M | $62M | $64M | $0 | $0 | $0 | $6M | $6M | |
| Other Non-current Assets | $78.0K | $78.0K | $2M | $12M | $11M | $10M | $10M | $10M | $9M | $8M | $9M | · | · | · | $0 | $17.0K | |
| Total Assets | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Accounts Payable | $5M | $5M | $2M | $3M | $2M | $3M | $3M | $2M | $2M | $2M | $2M | $409.0K | $353.0K | $2M | $570.0K | $1M | |
| Accrued Liabilities | $4M | $3M | $11M | $5M | $6M | $5M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | $2M | $4M | |
| Current Liabilities | $8M | $9M | $43M | $26M | $7M | $8M | $7M | $5M | $10M | $10M | $10M | $2M | $2M | $3M | $3M | $5M | |
| Capital Leases | $0 | $293.0K | $330.0K | $359.0K | $387.0K | $383.0K | $394.0K | $450.0K | $453.0K | $480.0K | $321.0K | · | · | · | $0 | $34.0K | |
| Deferred Tax | · | · | $0 | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $5M | $0 | $0 | $0 | $248.0K | $248.0K | |
| Other Non-current Liabilities | $716.0K | $1M | $2M | $778.0K | $745.0K | $716.0K | $685.0K | $643.0K | $609.0K | $599.0K | $587.0K | · | · | · | $0 | · | |
| Total Liabilities | $16M | $11M | $129M | $109M | $105M | $89M | $84M | $82M | $88M | $85M | $83M | $2M | $2M | $3M | $3M | $5M | |
| Long-term Debt | · | · | $0 | $0 | $17M | $15M | $14M | $15M | $14M | $14M | $13M | · | · | · | $0 | · | |
| Total Debt | $0 | $0 | · | $18M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $1.0K | $14.0K | $55.0K | $54.0K | $53.0K | $44.0K | $44.0K | $43.0K | $43.0K | $43.0K | $43.0K | $36.0K | $36.0K | $36.0K | $36.0K | $36.0K | |
| Paid-in Capital | $460M | $436M | $419M | $416M | $413M | $408M | $407M | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-500M | $-425M | $-460M | $-421M | $-408M | $-392M | $-376M | $-364M | $-359M | $-331M | $-320M | $-311M | $-305M | $-301M | $-288M | $-283M | |
| AOCI | $4M | $5M | $6M | $6M | $6M | $2M | $-35.0K | $3M | $1M | $2M | $3M | $516.0K | $257.0K | $38.0K | $-289.0K | $-253.0K | |
| Stockholders' Equity | $-35M | $16M | $-36M | $1M | $12M | $19M | $30M | $45M | $47M | $74M | $85M | $83M | $87M | $90M | $101M | $105M | |
| Liabilities + Equity | $124M | $27M | $94M | $110M | $117M | $107M | $114M | $127M | $135M | $159M | $168M | $85M | $89M | $93M | $104M | $110M | |
| Shares Outstanding | 1,017,063 | 13,790,794 | 55,725,291 | 54,494,965 | 53,624,180 | 44,089,142 | 44,001,643 | 43,276,606 | 43,276,606 | 43,215,233 | 42,973,215 | 36,343,632 | 36,327,995 | 36,278,433 | 36,136,480 | 36,130,306 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $41.0K | $36.0K | $39.0K | $36.0K | $35.0K | $32.0K | $16.0K | $86.0K | $44.0K | $40.0K | $304.0K | $0 | $1.0K | $17.0K | $42.0K | $40.0K | |
| Stock-based Comp | $12M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $694.0K | |
| Operating Cash Flow | $-19M | $-8M | $-10M | $-10M | $-11M | $-10M | $-8M | $-7M | $-9M | $-8M | $-6M | $-5M | $-4M | $-4M | $-6M | $-7M | |
| CapEx | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K | $39.0K | $39.0K | $24.0K | $0 | $0 | $136.0K | $78.0K | $50.0K | |
| Investing Cash Flow | $8M | $12M | $8M | $-2M | $6M | $11M | $11M | $7M | $-5M | $9M | $5M | $4M | $-20M | $6M | $19M | $-9M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $109M | $9M | $2M | $1M | $14M | $87.0K | $0 | $-5M | $35.0K | $190.0K | $57.0K | $10.0K | $26.0K | $50.0K | $-18.0K | $-5.0K | |
| Net Change in Cash | $98M | $12M | $-643.0K | $-10M | $9M | $2M | $4M | $-5M | $-14M | $1M | $-880.0K | $-1M | $-24M | $2M | $13M | $-15M | |
| Free Cash Flow | · | $-8M | · | · | · | $-10M | · | · | · | $-8M | · | · | · | $-4M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -62.6% | 53.7% | · | -11.4% | -12.7% | -11.3% | · | -5.2% | -24.8% | -8.8% | · | -5.5% | -4.7% | -11.7% | · | -6.2% | |
| ROE | 640.0% | 209.7% | · | -58.5% | -54.7% | -32.4% | · | -8.6% | -41.4% | -13.6% | · | -5.7% | -4.9% | -12.5% | · | -6.7% | |
| ROIC | · | · | · | · | · | -80.2% | · | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.5 | 2.9 | · | 1.1 | 5.0 | 4.0 | · | 9.5 | 6.1 | 7.2 | · | 37.8 | 45.4 | 29.7 | · | 19.9 | |
| Quick Ratio | 13.6 | 2.1 | · | 0.2 | 2.3 | 0.9 | · | 8.8 | 5.8 | 6.9 | · | 9.5 | 10.6 | 13.6 | · | 4.4 | |
| Debt / Equity | 0.0 | 0.0 | · | 16.5 | · | · | · | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-34.73 | $1.14 | · | $0.02 | $0.22 | $0.42 | · | $1.04 | $1.09 | $1.72 | · | $2.29 | $2.39 | $2.49 | · | $2.89 | |
| Cash Flow / Share | · | $-0.83 | · | · | · | $-0.22 | · | · | · | $-0.19 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $114.04 | $1.32 | · | $0.12 | $0.31 | $0.18 | · | $1.10 | $1.37 | $1.57 | · | $0.57 | $0.57 | $1.17 | · | $0.60 | |
| EPS (TTM) | $-10.43 | $-66.87 | · | $-72.70 | $-72.58 | $-4.47 | · | $-1.24 | $-1.26 | $-0.76 | · | $-0.72 | $-0.79 | $-1.16 | · | $-2.23 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-92M | $-33M | · | $-57M | $-49M | $-61M | · | $-53M | $-53M | $-30M | · | $-28M | $-31M | $-42M | · | $-70M | |
| Market Cap | $19M | $1M | · | $89M | $88M | $59M | · | $34M | $32M | $46M | · | $41M | $55M | $57M | · | $48M | |
| Enterprise Value | $-97M | $-17M | · | $100M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -1.7 | -0.0 | · | -0.0 | -0.0 | -0.3 | · | -0.6 | -0.6 | -1.4 | · | -1.6 | -1.9 | -1.3 | · | -0.6 | |
| P/B | -0.5 | 0.1 | · | 83.9 | 7.5 | 3.2 | · | 0.7 | 0.7 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Tangible Book | · | 0.1 | · | · | · | · | · | · | · | · | · | 0.5 | 0.6 | 0.6 | · | 0.5 | |
| P / Cash Flow | · | -0.2 | · | · | · | -6.1 | · | · | · | -5.5 | · | · | · | -15.9 | · | · | |
| Earnings Yield | -57.3% | -66207.9% | · | -4460.1% | -4398.8% | -336.1% | · | -159.8% | -168.0% | -71.7% | · | -64.3% | -52.5% | -74.4% | · | -167.7% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Gelir | $-84M | $-57M | $-31M | $-52M | $-90M |
| Seyreltilmiş Hisse Başı Kâr | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | -0.5 | · | · | · | · |
| Cari Oran | 0.5 | 6.1 | 8.1 | 30.5 | 7.9 |
| Cari Oran | 0.1 | 5.6 | 7.8 | 29.4 | 7.5 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-42M | $-32M | $-18M | $-44M | $-63M |
Kurumsal Sahipler (13F) 2 dosya · $7.1M toplam · Tarih itibarıyla 31 Aralık 2025
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
2
Tutulan Değer
$7.1M
Yeni pozisyonlar
15
Çıkan pozisyonlar
35
Kurumsal faaliyet — Q1 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 15 (-11 önceki Ç'ye göre) | 35 (+31 önceki Ç'ye göre) | 8 (-13 önceki Ç'ye göre) | 12 (+7 önceki Ç'ye göre) | -5.2M |
Q4 2025 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6.981.450 | 2.084.015 | 98,72% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $90.785 | 27.100 | 1,28% | Hisse senetleri |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| David A. Lamond | 13 Kasım 2024 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 24 içeriden öğrenenler · 14 yöneticiler · 14 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Dirk Thye | CEO and CMO | 23 Ocak 2026 A | 739.885 | 0 | 0 | $0 |
| Christopher P. Lowe | Interim CEO, COO & CFO | 03 Mart 2022 A | 265.000 | 0 | 0 | $0 |
| Casey Lynch | Chief Executive Officer | 03 Ocak 2022 A | 109.895 | 0 | 0 | $0 |
| Charles S. Ryan | President | 23 Ocak 2026 A | 130.009 | 0 | 0 | $0 |
| Brendan Hannah | CBO, COO & CCO | 23 Ocak 2026 A | 361.827 | 0 | 0 | $0 |
| Brigette Roberts | Chief Corp. Affairs Officer | 18 Mayıs 2026 A | · | 0 | 0 | $0 |
| Guenter Janhofer | Chief Scientific Officer | 23 Ekim 2023 A | · | 0 | 0 | $0 |
| Ted Monohon | Chief Accounting Officer & VP | 06 Mart 2023 S | 27.440 | 0 | 0 | $0 |
| Karen L. Smith | Chief Medical Officer | 01 Şubat 2023 A | 194.690 | 0 | 0 | $0 |
| Leslie Holsinger | EVP, Preclinical Development | 06 Haziran 2022 F | 148.080 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | Chief Legal & Adm. Officer | 06 Haziran 2022 S | 122.500 | 0 | 0 | $0 |
| Michael J. Detke | Chief Medical Officer | 03 Mart 2022 A | 140.000 | 0 | 0 | $0 |
| Stephen S. Dominy | Chief Scientific Officer | 03 Ocak 2022 A | 1.217.086 | 0 | 0 | $0 |
| Kristen Gafric | SVP, Legal & Administration | 06 Şubat 2020 A | · | 0 | 0 | $0 |
| David Lamond | Yönetim kurulu üyesi | 11 Haziran 2026 A | 2.347.545 | 0 | 0 | $0 |
| Christopher J. Senner | Yönetim kurulu üyesi | 11 Haziran 2026 A | · | 0 | 0 | $0 |
| June Bray | Yönetim kurulu üyesi | 02 Ocak 2026 A | · | 0 | 0 | $0 |
| Margaret Mcloughlin | Yönetim kurulu üyesi | 02 Ocak 2026 A | 8.000 | 0 | 0 | $0 |
| Luca Benatti | Yönetim kurulu üyesi | 26 Aralık 2025 S | 39.179 | 0 | 1 | $-173.500 |
| Rajiv Patni | Yönetim kurulu üyesi | 04 Haziran 2025 A | · | 0 | 0 | $0 |
| Una S Ryan | Yönetim kurulu üyesi | 04 Haziran 2025 A | 2.875 | 0 | 0 | $0 |
| Philip S Low | Yönetim kurulu üyesi | 19 Mayıs 2022 A | 63.974 | 0 | 0 | $0 |
| Marwan Sabbagh | Yönetim kurulu üyesi | 14 Mart 2022 A | · | 0 | 0 | $0 |
| Kevin Young | Yönetim kurulu üyesi | 08 Haziran 2020 A | 30.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 1 ETF tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 12.044 SH | 19 Ağustos 2026 | Günlük |
QNCX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 13 analist
AL
Medyan hedef
$70.00
+139,7%
4 30,8%
Güçlü Al
5 38,5%
Al
4 30,8%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
7 analist · 2026-10-04Ortalama hedef $75.43 +158,3%
← Tüm hedeflerin altında
Mevcut fiyat $29.20
Düşük$65.00
Ortalama$75.43
Yüksek$98.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| QNCX | $187M | -2.0 | · | · | 700.5% | · |
| ALGS | $58M | -3.8 | -39.5% | -1106.7% | -31.1% | · |
| ELUT | · | 0.8 | -15.0% | 434.2% | -753.4% | 53.7% |
| BYSI | · | · | · | · | 3.1% | · |
| ABVC | $53M | -5.5 | 234.3% | · | -128.2% | · |
| MCRB | $142M | 23.2 | · | 721.9% | 14.8% | · |
| ATYR | $77M | -1.0 | -19.1% | -39009.5% | -107.8% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 14, 2026